MY150214A - Kinesin inhibitors as cancer therapeutics - Google Patents

Kinesin inhibitors as cancer therapeutics

Info

Publication number
MY150214A
MY150214A MYPI2010002030A MYPI20102030A MY150214A MY 150214 A MY150214 A MY 150214A MY PI2010002030 A MYPI2010002030 A MY PI2010002030A MY PI20102030 A MYPI20102030 A MY PI20102030A MY 150214 A MY150214 A MY 150214A
Authority
MY
Malaysia
Prior art keywords
compounds
cancer therapeutics
kinesin inhibitors
treatment
substituted imidazole
Prior art date
Application number
MYPI2010002030A
Other languages
English (en)
Inventor
Abrams Tinya
Paul A Barsanti
Duhl David
Faure Michel
Paul A Renhowe
Walter Annette Olga
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY150214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY150214A publication Critical patent/MY150214A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2010002030A 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics MY150214A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
MY150214A true MY150214A (en) 2013-12-13

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010002030A MY150214A (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Country Status (30)

Country Link
US (2) US8252832B2 (https=)
EP (1) EP2229170B1 (https=)
JP (1) JP5501976B2 (https=)
KR (1) KR20100098394A (https=)
CN (1) CN101939005B (https=)
AR (1) AR069676A1 (https=)
AU (1) AU2008337570B2 (https=)
BR (1) BRPI0821248A2 (https=)
CA (1) CA2708822A1 (https=)
CL (1) CL2008003707A1 (https=)
CO (1) CO6290651A2 (https=)
CR (1) CR11412A (https=)
DO (1) DOP2010000175A (https=)
EA (1) EA018014B1 (https=)
EC (1) ECSP10010248A (https=)
ES (1) ES2459442T3 (https=)
GE (1) GEP20125647B (https=)
GT (1) GT201000172A (https=)
IL (1) IL205831A0 (https=)
MA (1) MA31872B1 (https=)
MY (1) MY150214A (https=)
NI (1) NI201000091A (https=)
NZ (1) NZ585142A (https=)
PA (1) PA8807801A1 (https=)
PE (1) PE20091451A1 (https=)
SM (1) SMP201000095B (https=)
TN (1) TN2010000204A1 (https=)
TW (1) TW200930704A (https=)
UY (1) UY31532A1 (https=)
WO (1) WO2009077448A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
EP2558452A2 (en) 2010-04-15 2013-02-20 Novartis AG Oxazole and thiazole compounds as ksp inhibitors
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc)
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
WO2019196111A1 (zh) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ksp) 억제제로서의n-(1-(1-벤질-4-페닐-1h-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
AU2008205169B2 (en) 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)

Also Published As

Publication number Publication date
CL2008003707A1 (es) 2009-06-05
AU2008337570B2 (en) 2012-04-05
IL205831A0 (en) 2010-11-30
CN101939005B (zh) 2015-12-16
AU2008337570A1 (en) 2009-06-25
JP2011506402A (ja) 2011-03-03
EA201000900A1 (ru) 2011-02-28
JP5501976B2 (ja) 2014-05-28
BRPI0821248A2 (pt) 2015-06-16
GEP20125647B (en) 2012-09-25
WO2009077448A1 (en) 2009-06-25
US8252832B2 (en) 2012-08-28
MA31872B1 (fr) 2010-11-01
UY31532A1 (es) 2009-08-03
CO6290651A2 (es) 2011-06-20
EP2229170B1 (en) 2014-01-22
PE20091451A1 (es) 2009-10-19
TW200930704A (en) 2009-07-16
US20130012560A1 (en) 2013-01-10
US8664256B2 (en) 2014-03-04
ECSP10010248A (es) 2010-07-30
DOP2010000175A (es) 2010-06-30
SMAP201000095A (it) 2010-09-10
CR11412A (es) 2010-06-30
NZ585142A (en) 2012-03-30
KR20100098394A (ko) 2010-09-06
GT201000172A (es) 2012-04-30
AR069676A1 (es) 2010-02-10
EP2229170A1 (en) 2010-09-22
US20090239922A1 (en) 2009-09-24
NI201000091A (es) 2011-03-15
ES2459442T3 (es) 2014-05-09
EA018014B1 (ru) 2013-04-30
CA2708822A1 (en) 2009-06-25
SMP201000095B (it) 2011-09-09
TN2010000204A1 (en) 2011-11-11
CN101939005A (zh) 2011-01-05
PA8807801A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
MY150214A (en) Kinesin inhibitors as cancer therapeutics
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
PH12016502066A1 (en) Methods of treating bladder cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
PH12013500102A1 (en) Crystalline forms of dimethoxy docetaxel and methods for preparing the same
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2010005703A (es) Antagonistas de acido nucleico entrelazado que eligen como objetivo al receptor de androgeno.
PH12012502194A1 (en) Indoles
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MX341197B (es) Compuestos de isoindol 5 - sustituidos.
MY147364A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
JO2886B1 (en) Useful compounds in the inhibition of CHK1
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2011008195A (es) Derivados de indol como agentes anticancer.
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2013002155A (es) Compuestos para el tratamiento de cancer.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
AU2019257509A1 (en) Androgen receptor modulators and methods for their use
EP4438127A3 (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2012103456A3 (en) Polycyclic beta lactam derivatives for the treatment of cancer